CN1317303C - 抗人腱生蛋白单克隆抗体 - Google Patents

抗人腱生蛋白单克隆抗体 Download PDF

Info

Publication number
CN1317303C
CN1317303C CNB038046342A CN03804634A CN1317303C CN 1317303 C CN1317303 C CN 1317303C CN B038046342 A CNB038046342 A CN B038046342A CN 03804634 A CN03804634 A CN 03804634A CN 1317303 C CN1317303 C CN 1317303C
Authority
CN
China
Prior art keywords
antibody
fragment
ser
purposes
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038046342A
Other languages
English (en)
Chinese (zh)
Other versions
CN1639192A (zh
Inventor
R·德圣缇斯
A·M·安纳斯塔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Sigma Co Ltd
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN1639192A publication Critical patent/CN1639192A/zh
Application granted granted Critical
Publication of CN1317303C publication Critical patent/CN1317303C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
CNB038046342A 2002-02-26 2003-02-20 抗人腱生蛋白单克隆抗体 Expired - Fee Related CN1317303C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35929902P 2002-02-26 2002-02-26
US60/359,299 2002-02-26

Publications (2)

Publication Number Publication Date
CN1639192A CN1639192A (zh) 2005-07-13
CN1317303C true CN1317303C (zh) 2007-05-23

Family

ID=27766061

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038046342A Expired - Fee Related CN1317303C (zh) 2002-02-26 2003-02-20 抗人腱生蛋白单克隆抗体

Country Status (19)

Country Link
US (3) US7438908B2 (https=)
EP (1) EP1478667B1 (https=)
JP (1) JP4488746B2 (https=)
KR (1) KR101048894B1 (https=)
CN (1) CN1317303C (https=)
AR (1) AR038700A1 (https=)
AT (1) ATE480564T1 (https=)
AU (1) AU2003215900B2 (https=)
BR (1) BR0307994A (https=)
CA (1) CA2475395C (https=)
CY (1) CY1111108T1 (https=)
DE (1) DE60334076D1 (https=)
DK (1) DK1478667T3 (https=)
ES (1) ES2352180T3 (https=)
MX (1) MXPA04008216A (https=)
PL (1) PL213216B1 (https=)
PT (1) PT1478667E (https=)
SI (1) SI1478667T1 (https=)
WO (1) WO2003072608A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040105A1 (it) * 2004-02-27 2004-05-27 Tecnogen Scpa Anticorpo monoclonale antitenascina umana.
EP2057193B1 (en) 2006-08-04 2013-12-18 Novartis AG Ephb3-specific antibody and uses thereof
CA2711843C (en) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
FR2930036B1 (fr) * 2008-04-11 2010-05-07 Assist Publ Hopitaux De Paris Procede de diagnostic d'une hypertension arterielle pulmonaire.
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
SG172984A1 (en) * 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-2 expression
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
WO2012051498A2 (en) 2010-10-15 2012-04-19 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
US8959638B2 (en) 2011-03-29 2015-02-17 Mcafee, Inc. System and method for below-operating system trapping and securing of interdriver communication
US8966624B2 (en) 2011-03-31 2015-02-24 Mcafee, Inc. System and method for securing an input/output path of an application against malware with a below-operating system security agent
US9032525B2 (en) 2011-03-29 2015-05-12 Mcafee, Inc. System and method for below-operating system trapping of driver filter attachment
US9262246B2 (en) 2011-03-31 2016-02-16 Mcafee, Inc. System and method for securing memory and storage of an electronic device with a below-operating system security agent
US8863283B2 (en) 2011-03-31 2014-10-14 Mcafee, Inc. System and method for securing access to system calls
US9087199B2 (en) 2011-03-31 2015-07-21 Mcafee, Inc. System and method for providing a secured operating system execution environment
US9038176B2 (en) 2011-03-31 2015-05-19 Mcafee, Inc. System and method for below-operating system trapping and securing loading of code into memory
US9317690B2 (en) 2011-03-28 2016-04-19 Mcafee, Inc. System and method for firmware based anti-malware security
US8966629B2 (en) 2011-03-31 2015-02-24 Mcafee, Inc. System and method for below-operating system trapping of driver loading and unloading
US8813227B2 (en) 2011-03-29 2014-08-19 Mcafee, Inc. System and method for below-operating system regulation and control of self-modifying code
US8925089B2 (en) 2011-03-29 2014-12-30 Mcafee, Inc. System and method for below-operating system modification of malicious code on an electronic device
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
WO2013088140A2 (en) * 2011-12-12 2013-06-20 Isis Innovation Limited Biomarker and use thereof
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
GB201602413D0 (en) * 2016-02-10 2016-03-23 Nascient Ltd Method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624659A (en) * 1993-03-19 1997-04-29 Duke University Method of treating brain tumors expressing tenascin
US6335014B1 (en) * 1998-06-17 2002-01-01 The Institute Of Physical And Chemical Research Medicament for suppressing cancer metastasis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687732A (en) * 1983-06-10 1987-08-18 Yale University Visualization polymers and their application to diagnostic medicine
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
ATE335072T1 (de) * 1993-05-28 2006-08-15 Scripps Research Inst Methoden für inhibition der cd14-abhängigen zellaktivierung
ITRM20020128A1 (it) 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624659A (en) * 1993-03-19 1997-04-29 Duke University Method of treating brain tumors expressing tenascin
US6335014B1 (en) * 1998-06-17 2002-01-01 The Institute Of Physical And Chemical Research Medicament for suppressing cancer metastasis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Antibody-guided three-step therapy for high grade glioma withyttrium-90 biotin. PAGANELLI G ET AL,EUROPEAN JOURNAL OF NUCLEAR MEDICINE,Vol.26 No.4 1999 *
Teascin in human neoplasia:Immunohistochemicalobservations using seven different clones of monoclonalantibodies. SHRESTHA PRASHANTA ET AL,INTERNATIONAL JOURNAL OF ONCOLOGY,Vol.8 No.4 1996 *

Also Published As

Publication number Publication date
KR20040086426A (ko) 2004-10-08
PL213216B1 (pl) 2013-01-31
AU2003215900B2 (en) 2008-09-25
AU2003215900A1 (en) 2003-09-09
MXPA04008216A (es) 2004-11-26
SI1478667T1 (sl) 2010-12-31
CN1639192A (zh) 2005-07-13
EP1478667A1 (en) 2004-11-24
JP2005534615A (ja) 2005-11-17
KR101048894B1 (ko) 2011-07-13
ES2352180T3 (es) 2011-02-16
JP4488746B2 (ja) 2010-06-23
DE60334076D1 (de) 2010-10-21
US20110020219A1 (en) 2011-01-27
US20040005643A1 (en) 2004-01-08
CY1111108T1 (el) 2015-06-11
US8048417B2 (en) 2011-11-01
PT1478667E (pt) 2010-12-09
EP1478667B1 (en) 2010-09-08
PL372803A1 (en) 2005-08-08
US20050106145A1 (en) 2005-05-19
WO2003072608A1 (en) 2003-09-04
ATE480564T1 (de) 2010-09-15
AR038700A1 (es) 2005-01-26
CA2475395C (en) 2011-08-02
CA2475395A1 (en) 2003-09-04
BR0307994A (pt) 2004-12-07
US7438908B2 (en) 2008-10-21
HK1078589A1 (en) 2006-03-17
DK1478667T3 (da) 2010-12-20

Similar Documents

Publication Publication Date Title
CN1317303C (zh) 抗人腱生蛋白单克隆抗体
CN1235911C (zh) 多细胞因子－抗体复合物
CN1105728C (zh) 用于治疗il4介导疾病的重组il4抗体
CN1076966A (zh) 抗人白细胞介素-4的人性化单克隆抗体的克隆和表达
HK1042503A1 (zh) 表达以及分泌制管张素和endostatin的免疫融合物
CN1087681A (zh) 具有抗人体内病原菌感染的被动免疫力的新抗体
CN1203603A (zh) 由抗－Fc受体抗体组成的治疗化合物
CN1252076A (zh) 抗人抗原受体的新的生产方法及其用途
CN1620468A (zh) 新的抗igf－ir抗体及其应用
CN1494553A (zh) 改变的抗体及其使用方法
CN101035809A (zh) 抗tag－72的人源化单克隆抗体
CN101074261A (zh) Trail受体1和/或trail受体2特异性抗体及其应用
CN1235639A (zh) 重新构建的人抗hm1.24抗体
CN1662558A (zh) 人cd22特异性抗体及其治疗和诊断应用
CN1327388A (zh) 诱导抗独特型反应增强的修饰抗体
CN1809592A (zh) 识别n－乙醇酰gm3神经节苷脂的重组抗体和片段以及其在肿瘤诊断和治疗上的应用
CN1596313A (zh) 人源化的胶原抗体及相关方法
CN1585822A (zh) 抗体的多顺反子表达
CN1958615A (zh) 功能人源化抗人cd20抗体及其应用
CN1551783A (zh) 治疗多发性骨髓瘤的方法
CN1078250C (zh) 抗免疫球蛋白等模式标本的重整形单克隆抗体
CN1151184A (zh) 对细胞周期非依赖的神经胶质瘤表面抗原特异的人单克隆抗体
CN1355846A (zh) 用于下调节白细胞介素5活性的方法
CN1649901A (zh) 人癌胚抗原(cea)的特异性抗体片段
CN1946740A (zh) 抗人腱生蛋白单克隆抗体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1078589

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20171207

Address after: Milan Italy

Patentee after: Alpha Sigg Ma company

Address before: Rome Italy

Patentee before: Sigma-Tau Industrie Farmaceutiche Riunite S. P. A.

CP01 Change in the name or title of a patent holder

Address after: Milan Italy

Patentee after: Alpha sigma Co., Ltd

Address before: Milan Italy

Patentee before: Alpha Sigg Ma Co.

CP01 Change in the name or title of a patent holder
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070523

Termination date: 20210220

CF01 Termination of patent right due to non-payment of annual fee